{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:13:47Z","timestamp":1787004827565,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1053\/j.seminhematol.2012.04.003","type":"journal-article","created":{"date-parts":[[2012,6,20]],"date-time":"2012-06-20T05:08:12Z","timestamp":1340168892000},"page":"258-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["The Immunoproteasome as a Target in Hematologic Malignancies"],"prefix":"10.1053","volume":"49","author":[{"given":"Deborah J.","family":"Kuhn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2012.04.003_bib1","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1124\/pr.55.3.4","article-title":"Specific targeted therapy of chronic myelogenous leukemia with imatinib","volume":"55","author":"Deininger","year":"2003","journal-title":"Pharmacol Rev"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib3","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib4","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib5","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"23","author":"O'Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib6","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1182\/blood-2008-08-172734","article-title":"The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition","volume":"113","author":"Bianchi","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib7","first-page":"6316","article-title":"The proteasome as a target for cancer therapy","volume":"9","author":"Voorhees","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1126\/science.7725097","article-title":"Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution","volume":"268","author":"Lowe","year":"1995","journal-title":"Science"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/oxfordjournals.jbchem.a003084","article-title":"Structure determination of the constitutive 20S proteasome from bovine liver at 2.75 A resolution","volume":"131","author":"Unno","year":"2002","journal-title":"J Biochem"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib10","doi-asserted-by":"crossref","first-page":"12215","DOI":"10.1016\/S0021-9258(18)63843-8","article-title":"The multicatalytic proteinase","volume":"264","author":"Rivett","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1097-2765(00)80341-X","article-title":"Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown","volume":"4","author":"Kisselev","year":"1999","journal-title":"Mol Cell"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s002510050246","article-title":"Sequence and expression of mouse proteasome activator PA28 and the related autoantigen Ki","volume":"46","author":"Jiang","year":"1997","journal-title":"Immunogenetics"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib13","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1006\/bbrc.2000.3676","article-title":"Tissue distribution of constitutive proteasomes, immunoproteasomes, and PA28 in rats","volume":"277","author":"Noda","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib14","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1182\/blood-2009-05-223677","article-title":"Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome","volume":"114","author":"Parlati","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib15","doi-asserted-by":"crossref","first-page":"9213","DOI":"10.1073\/pnas.91.20.9213","article-title":"Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7","volume":"91","author":"Gaczynska","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib16","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/365264a0","article-title":"Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes","volume":"365","author":"Gaczynska","year":"1993","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib17","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev.immunol.17.1.739","article-title":"Degradation of cell proteins and the generation of MHC class I-presented peptides","volume":"17","author":"Rock","year":"1999","journal-title":"Annu Rev Immunol"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib18","doi-asserted-by":"crossref","first-page":"9241","DOI":"10.1073\/pnas.0501711102","article-title":"IFN-\u03b3-induced immune adaptation of the proteasome system is an accelerated and transient response","volume":"102","author":"Heink","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib19","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1172\/JCI29832","article-title":"Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection","volume":"116","author":"Shin","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib20","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1182\/blood.V98.4.1108","article-title":"Tumor necrosis factor-alpha induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface","volume":"98","author":"Hallermalm","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib21","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1084\/jem.179.3.901","article-title":"Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes","volume":"179","author":"Boes","year":"1994","journal-title":"J Exp Med"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.0105-2896.2005.00308.x","article-title":"Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing","volume":"207","author":"Strehl","year":"2005","journal-title":"Immunol Rev"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/1389203043379774","article-title":"Proteasome function in antigen presentation: immunoproteasome complexes, peptide production, and interactions with viral proteins","volume":"5","author":"Rivett","year":"2004","journal-title":"Curr Protein Pept Sci"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib24","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1016\/S0021-9258(17)41897-7","article-title":"Identification, purification, and characterization of a high molecular weight, ATP-dependent activator (PA700) of the 20 S proteasome","volume":"269","author":"Chu-Ping","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib25","doi-asserted-by":"crossref","first-page":"22362","DOI":"10.1016\/S0021-9258(18)41680-8","article-title":"Multiple forms of the 20 S multicatalytic and the 26 S ubiquitin\/ATP-dependent proteases from rabbit reticulocyte lysate","volume":"267","author":"Hoffman","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib26","doi-asserted-by":"crossref","first-page":"27994","DOI":"10.1074\/jbc.272.44.27994","article-title":"Relative functions of the alpha and beta subunits of the proteasome activator, PA28","volume":"272","author":"Song","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/art.33333","article-title":"Novel proteasome inhibitors have a beneficial effect in murine lupus via the dual inhibition of type 1 interferon and autoantibody secreting cells","volume":"64","author":"Ichikawa","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib28","doi-asserted-by":"crossref","first-page":"634","DOI":"10.4049\/jimmunol.0903182","article-title":"Prevention of experimental colitis by a selective inhibitor of the immunoproteasome","volume":"185","author":"Basler","year":"2010","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib29","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nm.1978","article-title":"A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis","volume":"15","author":"Muchamuel","year":"2009","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib30","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1172\/JCI28804","article-title":"Proteasome-mediated degradation of I\u03baB\u03b1 and processing of p105 in Crohn disease and ulcerative colitis","volume":"116","author":"Visekruna","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib31","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib32","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1182\/blood-2008-07-171637","article-title":"Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors","volume":"113","author":"Kuhn","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib33","doi-asserted-by":"crossref","first-page":"13946","DOI":"10.1021\/bi970666e","article-title":"Reactions of [C-14]-3,4-dichloroisocoumarin with subunits of pituitary and spleen multicatalytic proteinase complexes (proteasomes)","volume":"36","author":"Orlowski","year":"1997","journal-title":"Biochemistry"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib34","doi-asserted-by":"crossref","first-page":"9768","DOI":"10.1021\/bi990735k","article-title":"Components of the bovine pituitary multicatalytic proteinase complex (proteasome) cleaving bonds after hydrophobic residues","volume":"38","author":"Cardozo","year":"1999","journal-title":"Biochemistry"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib35","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.chembiol.2007.03.008","article-title":"LMP2-specific inhibitors: chemical genetic tools for proteasome biology","volume":"14","author":"Ho","year":"2007","journal-title":"Chem Biol"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib36","doi-asserted-by":"crossref","first-page":"35869","DOI":"10.1074\/jbc.M303725200","article-title":"The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites","volume":"278","author":"Kisselev","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminhematol.2012.04.003_bib37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2141.2010.08491.x","article-title":"PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo","volume":"152","author":"Singh","year":"2011","journal-title":"Br J Haematol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196312000261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196312000261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:21:07Z","timestamp":1758522067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196312000261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0037196312000261"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2012.04.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Immunoproteasome as a Target in Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2012.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}